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ORIGINAL ARTICLE
A common biological basis of obesity and nicotine addiction
TE Thorgeirsson1, DF Gudbjartsson1, P Sulem1, S Besenbacher1,2, U Styrkarsdottir1, G Thorleifsson1, GB Walters1, TAG Consortium9,
Oxford-GSK Consortium9, ENGAGE consortium9, H Furberg3, PF Sullivan4, J Marchini5,6, MI McCarthy5,7, V Steinthorsdottir1,
U Thorsteinsdottir1,8 and K Stefansson1,8
Smoking inﬂuences body weight such that smokers weigh less than non-smokers and smoking cessation often leads to weight
increase. The relationship between body weight and smoking is partly explained by the effect of nicotine on appetite and
metabolism. However, the brain reward system is involved in the control of the intake of both food and tobacco. We evaluated the
effect of single-nucleotide polymorphisms (SNPs) affecting body mass index (BMI) on smoking behavior, and tested the 32 SNPs
identiﬁed in a meta-analysis for association with two smoking phenotypes, smoking initiation (SI) and the number of cigarettes
smoked per day (CPD) in an Icelandic sample (N¼ 34 216 smokers). Combined according to their effect on BMI, the SNPs correlate
with both SI (r¼ 0.019, P¼ 0.00054) and CPD (r¼ 0.032, P¼ 8.0 10 7). These ﬁndings replicate in a second large data set
(N¼ 127 274, thereof 76 242 smokers) for both SI (P¼ 1.2 10 5) and CPD (P¼ 9.3 10 5). Notably, the variant most strongly
associated with BMI (rs1558902-A in FTO) did not associate with smoking behavior. The association with smoking behavior is not
due to the effect of the SNPs on BMI. Our results strongly point to a common biological basis of the regulation of our appetite for
tobacco and food, and thus the vulnerability to nicotine addiction and obesity.
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INTRODUCTION
Smoking and obesity are major risk factors for many serious
diseases.1,2 Eating and smoking are behavioral traits that are at
least in part controlled by the same reward mechanisms.3
Genome-wide association studies (GWAS) have yielded 32
single-nucleotide polymorphisms (SNPs) associated with body
mass index (BMI).4 Smoking and SNPs associated with increased
smoking quantity have been shown to correlate with lower BMI.5,6
According to the World Health Organization (WHO), more than
one billion people smoke and over 400 million people are obese (BMI
430 kgm 2), with both prevalences rising (see url section). Eating
can become compulsive, and the neurobiological processes relating
to overindulgence in food overlap with those involved in substance
abuse and addiction.3 All drugs of abuse have been shown to
increase dopamine in the mesolimbic reward system, and studies of
both human brain images3 and animal brains7 have revealed that
similar neurocircuits are involved in the regulation of rewarding and
reinforcement in drug addiction and compulsive eating. Based on
the many similarities between hyperphagia and excessive drug use
in addiction, it has even been suggested that some forms of obesity
should be included as a diagnosis in future editions of the
Diagnostic and Statistical Manual of Mental Disorders.8,9
Smoking inﬂuences body weight, such that smokers weigh
less than non-smokers, and smoking cessation is often accom-
panied by an increase in weight.5 These effects have been largely
attributed to nicotine that increases the metabolic rate and
suppresses appetite. Although increased food intake upon
smoking cessation is partly explained by a reward substitution
mechanism, as food intake is increased to make up for the lack of
nicotine, the absence of nicotine has also been shown to increase
the reward value of certain foods.10 At the molecular level, these
effects are most likely achieved through activation of the nicotinic
acetylcholine receptors. The melanocortin (MC) system has a key
role in regulating body weight,11 and nicotine was recently shown
to interact directly with the MC system in the brain through
activation of a3b4 nicotinic acetylcholine receptors on pro-
opiomelanocortin (POMC) neurons12 in the arcuate nucleus of
the hypothalamus. The POMC neurons project to secondary
neurons inﬂuencing appetite, and nicotine activation leads to the
release of melanocortin-4 agonists activating MC4 receptors in the
paraventricular nucleus producing appetite suppression, an effect
that is absent from POMC KO mice.12
However, the relationship between smoking phenotypes and
obesity is more complicated than can be accounted for by the known
effects of nicotine on appetite and metabolism. This is evident from
the fact that the number of cigarettes smoked per day (CPD) corre-
lates with elevated BMI.13,14 Thus, although smokers weigh less than
non-smokers, heavy smokers indeed weigh more than light smokers.
BMI and smoking data are widely available from various studies
and large sample sizes have been obtained for GWAS of BMI4 and
some smoking phenotypes,15–17 and these studies have
uncovered a number of variants associating with obesity (BMI)
and with smoking behavior. The variant most strongly correlating
with CPD,15–17 rs1051730-A/rs16969968-A, correlates with reduced
BMI both in current and former smokers, but does not have an
impact on the BMI of never smokers.6 This observation is
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consistent with the notion that smoking inﬂuences body weight
through nicotine’s effects on body and brain, the increase of
metabolic rate and suppression of appetite. Here we report how
variants correlating with BMI inﬂuence smoking behavior.
MATERIALS AND METHODS
Study subjects
Written informed consent was obtained from all subjects. Inclusion in the
study required the availability of genotypes from ongoing SNP array typing
in Iceland or previous GWAS,15–17 and the study populations have all been
described previously.15–17 The GWAS of smoking initiation (SI) involved
comparison of ever smokers and never smokers, and the studies of
smoking quantity probed CPD as a quantitative trait among smokers only.
The deﬁnitions of smokers and never smokers varied somewhat between
studies,15–17 as questions addressing smoking behavior varied with most
studies probing for regular smoking over a certain period of time.
Questions probing for smoking quantity also varied between studies, and
for analysis of smoking quantity we used CPD data for smokers in
categories with each category representing 10 CPD (effect size of 0.1¼ 1
CPD).15–17 CPD at the time of smoking was used for past smokers, and
never smokers were excluded from analysis of CPD. All subjects were of
European descent. The total sample sizes were N¼ 100 860 and
N¼ 161 490 for CPD and SI, respectively.
Icelandic study design
A generalized form of linear regression was used to test the correlation
between quantitative traits (BMI and height) and smoking phenotypes
(CPD and SI) in Iceland. The generalized form assumes that the smoking
behavior of related individuals is correlated proportional to the kinship
between them rather than assuming that the smoking phenotypes of all
individuals are independent. Let y be the vector of smoking behavior
measurements, and let x be the vector of BMI or height measurements. We
assume that the expectation of the smoking behavior depends linearly on
BMI or height, Ey¼ aþbx, and that the variance–covariance matrix of the
smoking behavior depends only on the pairwise kinship between the
study participants, Var(y)¼ 2s2F, where
Fij ¼
1
2 ; i ¼ j
2rkij ; i 6¼ j

:
is based on the kinship between individuals as estimated from the
Icelandic genealogical database (kij) and an estimate of the heritability of
the trait (r). Assuming normally distributed errors, the maximum likelihood
method gives estimates for b, which will asymptotically follow a normal
distribution and can be used to estimate the correlation between height
and BMI on the one side and CPD and SI on the other.
In order to test the correlation between the set of 32 BMI SNPs or the set
of 180 height SNPs and smoking behavior, the same type of analysis was
performed replacing the observed BMI and height with the BMI and height
predicted based on the sets of 32 and 180 SNPs. We shall describe how this
was achieved for BMI, the analysis for height being conceptually identical.
For each of the 32 SNPs reported to associate with BMI, let fi be its minor
allele frequency and gi be its published effect on BMI. For an individual
with gi minor alleles at SNP i, the set of 32 BMI SNPs predict a BMI of
X32
i¼1
ðgi  2fiÞgi
Conditional independence
We observe a correlation between the 32 BMI SNPs and smoking behavior.
The 32 BMI SNPs associate with BMI and BMI associates with CPD.
The question then arises of whether the correlation between the
32 BMI SNPs and CPD is all going through BMI. In other words, are the 32
BMI SNPs and CPD correlated conditional on BMI? Assuming that the
32 BMI SNPs and CPD are independent conditional on BMI, then
the correlation between the 32 BMI SNPs and CPD will be the product
of the correlation between the 32 BMI SNPs and BMI and the correlation
between BMI and CPD. Denoting the estimator for the correlation between
the 32 BMI SNPs and BMI with cBMISNPs;BMI, and the variance of the estimator
with VarðcBMISNPs;BMIÞ, and similarly for the correlation between BMI and
CPD. Then, cBMISNPs;BMIcBMI;CPD is an estimator of the correlation between
the 32 BMI SNPs and CPD, assuming conditional independence, and
Var cBMISNPs;BMI
 
Var cBMI;CPD
 þ Var cBMISNPs;BMI c2BMI;CPDþ c2BMISNPS;BMIVar cBMI;CPD 
gives an estimate of the variance of the estimator. A standard test for the
mean of two samples can now be applied to test the difference between
the observed correlation between the 32 BMI SNPs and CPD and the
correlation predicted based on the 32 BMI SNPs and CPD being
independent conditional on BMI.
Replication outside of Iceland
The non-Icelandic studies shared only summary results from the genome-
wide smoking behavior association scans in the form of effect sizes, P-values
and allele frequencies. The B2.5 million SNPs from the HapMap dataset
were imputed and tested for association within each study population.15–17
The signiﬁcance levels of each study population were adjusted individually
using the method of genomic control.18 We used standard ﬁxed-effects
additive meta-analysis to combine the results for each SNP. After combining
the results from all the populations, we again applied the method of
genomic control and adjusted both smoking phenotypes accordingly
(lGC¼ 1.10 and lGC¼ 1.06 for SI and CPD, respectively).
As data were not available on the individual level, we could not predict
SI and CPD on the individual level as was done in Iceland. In order to test
for the association of the 32 SNPs associating with BMI and the 180 SNPs
associating with height with smoking behavior, we weighted the
combined signiﬁcance over all the populations of each SNP by the
expected z-score associated with the SNP, assuming that the effect on
smoking behavior was proportional to the effect on BMI or height as
follows. Again let us take BMI as an example. For each of the 32 SNPs
reported to associate with BMI, let fi be its minor allele frequency and gi be
its published effect on BMI. We denote the unknown effect of each SNP on
smoking behavior with bi and our assumption about the SNP’s effect on
smoking behavior being proportional to the SNP’s effect on BMI can be
stated as bi¼ kgi for some constant k. Quantifying the signiﬁance of the
association of each SNP with smoking behavior by its z-score zi, maximal
power is achieved by weighing the SNPs according to the expected
z-score. The expected z-score for the ith SNP is proportional to bi
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
fið1  fiÞ
p
,
which we assume is proportional to gi
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2fið1  fiÞ
p
, which we will refer to
as wi and use to weigh the smoking behavior z-scores of the 32 BMI SNPs
together: z ¼
P32
i¼1 wiziﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP32
i¼1 w
2
i
q .
RESULTS AND DISCUSSION
To study the correlation between obesity variants and smoking
phenotypes, we focused on the 32 SNPs associating with BMI
Table 1. Association of BMI, height and SNPs associating with BMI and height with smoking phenotypes in Iceland
CPD Smoking
From N Correlation (95% CI) P N Correlation (95% CI) P
BMI 33 620 0.095 (0.085, 0.106) 2.5 10 68 49 565  0.005 ( 0.014, 0.004) 0.29
32 BMI SNPs 24 618 0.032 (0.019, 0.045) 8.0 10 7 34 216 0.019 (0.008, 0.030) 0.00054
Height 33 875  0.004 ( 0.015, 0.007) 0.46 49 931  0.012 ( 0.021,  0.002) 0.013
180 Height SNPs 24 630 0.001 ( 0.011, 0.014) 0.84 34 231 0.004 ( 0.007, 0.015) 0.44
Abbreviations: BMI, body mass index; CI, confidence interval; SNP, single-nucleotide polymorphism.
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described in a recent report of a study of 249 796 subjects.4 We
weighted the 32 SNPs together based on their published effect on
BMI and tested the correlation with both CPD and SI in 49 565
chip-typed Icelanders (Table 1). We also tested the correlation
between the actual measured BMI and the smoking phenotypes in
a slightly larger set of Icelanders. For comparison, we performed a
corresponding study using Icelandic data on human height and
180 SNPs reported to inﬂuence human height in a recent study of
183 731 individuals19 (Table 1).
BMI associated with CPD (r¼ 0.095, P¼ 2.5 10 68) but not
SI (r¼  0.005, P¼ 0.29), whereas height did not associate with
CPD (r¼  0.004, P¼ 0.46) and showed only weak association
with SI (r¼  0.012, P¼ 0.013). The set of 32 BMI SNPs associated
with both CPD (r¼ 0.032, P¼ 8.0 10 7) and SI (r¼ 0.019,
P¼ 0.00054), whereas the set of 180 height SNPs associated with
neither smoking behavior (P¼ 0.84 and 0.44 for CPD and SI,
respectively).
The correlation between the set of 32 BMI SNPs and BMI and
the correlation between BMI and CPD predict a correlation
between the 32 BMI SNPs and CPD of 0.013, which is signiﬁcantly
lower than the observed correlation of 0.032 between the set of
32 BMI SNPs and CPD (P¼ 0.0033). The correlation between BMI
and SI is negative so that the predicted correlation between the 32
BMI SNPs and SI is also negative and even more signiﬁcantly
different from the observed correlation of 0.019 than from 0.
Hence, the observed associations between the BMI variants and
the smoking phenotypes are not explained by the direct
phenotypic correlations between BMI and smoking behavior.
To investigate the contributions of individual SNPs and to
replicate our observations in other populations, we looked up the
correlations of each of the 32 SNPs with CPD and SI, using data
from our previous studies outside of Iceland15–17 (N¼ 76 242 for
CPD, and N¼ 127 274 for SI). For these studies, we utilized the
ﬁxed-effect additive meta-analysis results for B2 500 000 SNPs
obtained using the inverse-variance method for each of the two
smoking phenotypes. Before conducting the meta-analysis, we
performed a genomic control correction of each study.18 The
combined w2-test statistics were still somewhat inﬂated by a factor
of lGC¼ 1.10 (SI) and lGC¼ 1.06 (CPD). The correlations between
the set of 32 BMI SNPs and the two smoking variables were
signiﬁcant in this replication sample with P¼ 1.2 10 5 and
9.3 10 5, for SI and CPD, respectively. Combined with Iceland,
the association between the 32 BMI SNPs and SI and CPD reached
a signiﬁcance of P¼ 1.2 10 7 and P¼ 1.6 10 9, respectively.
As expected, based on the correlations observed between the
combined set of the 32 BMI SNPs (Table 1), we observe
congruence in the effects that these SNPs have on BMI and
smoking behavior. For most of the SNPs, the allele that associates
with increased BMI also associates with both increased probability
of SI and higher CPD (Figure 1). We note that the effect sizes are
small and although the markers as a group clearly associate with
the smoking behaviors, further studies are required to determine
unequivocally which of the markers have an impact on smoking
behavior. The SNP by far most strongly associated with BMI
(rs1558902-A in FTO) represents a notable exception from the
trend observed and shows no evidence for association with either
CPD or SI.
Considering the 11 BMI SNPs most strongly associated with
smoking (Po0.05), 9 SNPs associate with smoking initiation and 4
with CPD (Supplementary Table 1 and Figure 1). For smoking
initiation the most signiﬁcant associations were to rs10767664-A
(effect¼ 0.050495, P¼ 1.14 10 6) in the Brain Neurotrophin
Factor gene (BDNF) and rs2867125-C (effect¼ 0.0397,
P¼ 0.000021) 45 kb upstream of the Transmembrane protein 18
gene (TMEM18), and for CPD the most signiﬁcant associations
were with rs2867125-C (effect¼ 0.286, P¼ 0.000346) (TMEM18)
and rs4771122-G (effect¼ 0.0193, P¼ 0.00048) in the mitochon-
drial translational initiation factor 3 gene (MTIF3). In addition to
rs286125-C (TMEM18), rs2815752-A (NEGR1) is among the top
markers (Po0.05) for both SI (effect¼ 0.186, P¼ 0.0244) and CPD
(effect¼ 0.0097, P¼ 0.0305). A SNP within the BDNF gene has
previously been shown to associate with smoking initiation
(rs6265-C).16 This SNP is in linkage disequilibrium with the BMI-
associated rs10767664 (r2¼ 0.85 in Iceland). The association with
SI remains signiﬁcant after removing rs10767664 (P¼ 1.3 10 5).
In summary, we have demonstrated that as a group, the 32
common variants identiﬁed in GWAS of BMI4 also have an impact
on the smoking behavior. A variant within the nAChR gene cluster
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Figure 1. Association of obesity variants with smoking initiation (SI)
and CPD. The effects on smoking behaviors are depicted vs the
effects on BMI from a large meta-analysis.4 (a) The effect on smoking
initiation vs the effect on BMI. (b) The effect on CPD vs the effect on
BMI. The BMI effect is in standard units, and the effects on SI and CPD
were obtained using a standard fixed-effects additive meta-analysis
to combine the results for each SNP from Iceland with additional
data from three large GWAS.15–17 The effects on SI are the b-values
from logistic regression treating ever smoking as the response and
the allele counts as covariates, and the GWAS of CPD used smoking
quantity in categories with each category representing 10 CPD
(effect size of 0.1¼ 1 CPD). The dots representing each data point are
color coded to indicate the p-value obtained as red (Po0.0001),
yellow (Po0.001), green (Po0.05) and black (PZ0.05) and the input
data are provided in (Supplementary Table 1).
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at chrs 15q25 (rs1051730-A) was discovered in GWAS of smoking
behavior20,21 and subsequently shown to correlate with reduced
BMI in smokers without an effect on the BMI of never smokers,6
thus most likely inﬂuencing BMI mainly through its effect on
smoking behavior. The variants studied here represent a different
class of SNPs affecting both BMI and smoking: They were found in
GWAS of BMI and inﬂuence BMI in both smokers and never
smokers, and the alleles correlating with elevated BMI tend to
increase the propensity to smoke and/or associate with increased
cigarette intake. We note that, in Iceland, the correlation between
the predicted BMI and observed BMI is similar for smokers
(0.15, P¼ 3.0 10 97, N¼ 20 462) and never smokers (0.13,
P¼ 7.2 10 33, N¼ 7910). The direction of this trend is
opposite to what would be expected based on the known
effects of nicotine on BMI, and inconsistent with an effect rooted
in nicotine-mediated increase of metabolic rate and suppression
of appetite. That the majority of variants known to associate with
elevation of BMI correlate with smoking behaviors in this manner
points to a common biological basis to regulation of the intake of
food and tobacco.
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